



DTIC FILE COPY

2

Institute Report No. 238

AD-A183 306

**Dermal Sensitization Potential  
of  
Ball Powder®  
in Guinea Pigs**

*Earl W. Morgan, DVM, MAJ VC  
John R.G. Ryabik, BS, SGT  
and  
Don W. Korte, PhD, MAJ MS*

**MAMMALIAN TOXICOLOGY BRANCH  
DIVISION OF TOXICOLOGY**

**DTIC**  
**ELECTE**  
AUG 13 1987  
S E

JULY 1987

Toxicology Series 127

LETTERMAN ARMY INSTITUTE OF RESEARCH  
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

This document has been approved  
for public release and sale; its  
distribution is unlimited.

7 119

Dermal Sensitization Potential of BALL POWDER® in Guinea Pigs  
(Toxicology Series 127)--Morgan, Ryabik, and Korte

Reproduction of this document in whole or in part is prohibited except with the permission of the Commander, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.

Destroy this report when it is no longer needed. Do not return it to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

In conducting the research described in this report, the investigation adhered to the "Guide for the Care and Use of Laboratory Animals," as promulgated by the Committee on Revision of the Guide for Laboratory Animal Facilities and Care, Institute of Laboratory Animal Resources, National Research Council.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)



(Signature and date)

17 Jul 87

This document has been approved for public release and sale; its distribution is unlimited.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

AD-A183306

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No 0704-0188  
Exp Date Jun 30, 1986

1a REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS			
2a SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION/AVAILABILITY OF REPORT <i>This document has been approved for public release and sale; its distribution is unlimited.</i>			
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE						
4 PERFORMING ORGANIZATION REPORT NUMBER(S)			5. MONITORING ORGANIZATION REPORT NUMBER(S)			
6a. NAME OF PERFORMING ORGANIZATION Mammalian Toxicology Branch Division of Toxicology		6b. OFFICE SYMBOL (if applicable) SGRD-UL-T-M	7a. NAME OF MONITORING ORGANIZATION US Army Biomedical Research and Development Laboratory			
6c. ADDRESS (City, State, and ZIP Code) Letterman Army Institute of Research Presidio of San Francisco CA 94129-6800			7b. ADDRESS (City, State, and ZIP Code) Fort Detrick, MD 21701-5010			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION US Army Medical Research and Development Command		8b. OFFICE SYMBOL (if applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER			
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick, MD 21701-5010			10. SOURCE OF FUNDING NUMBERS			
			PROGRAM ELEMENT NO. 62720A	PROJECT NO. 3E16270A835	TASK NO. AB	WORK UNIT ACCESSION NO. 180
11. TITLE (Include Security Classification) Dermal Sensitization Potential of BALL POWDER® in Guinea Pigs (UNCLASSIFIED)						
12. PERSONAL AUTHOR(S) Earl W. Morgan, DVM, MAJ, VC, John R.G. Ryabik, BS, SGT, Don W. Korte, Jr., PhD, MAJ, MS						
13a. TYPE OF REPORT Final		13b. TIME COVERED FROM 10 Apr TO 3 Jun 85		14. DATE OF REPORT (Year, Month, Day) July 1987		
15. PAGE COUNT 37						
16. SUPPLEMENTARY NOTATION						
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)			
FIELD	GROUP	SUB-GROUP	Dermal Sensitization, Toxicology, BALL POWDER® Nitrocel- lulose, Buehler Test, Guinea Pigs.			
19. ABSTRACT (Continue on reverse if necessary and identify by block number) BALL POWDER® was tested for its potential to produce sensitization via contact with the skin. Testing was performed on male guinea pigs using the Buehler Dermal Sensitization method. No evidence of dermal sensitization to BALL POWDER® was obtained in this study.						
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input checked="" type="checkbox"/> UNCLASSIFIED/UNLIMITED <input type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED			
22a. NAME OF RESPONSIBLE INDIVIDUAL Dov W. Korte Jr., PhD, MAJ, MS			22b. TELEPHONE (Include Area Code) (415) 561-2878		22c. OFFICE SYMBOL SGRD-UL-T	

# ABSTRACT

BALL POWDER<sup>®</sup> was tested for its potential to produce sensitization via contact with the skin. Testing was performed on male guinea pigs. The Buehler Dermal Sensitization method was used. No evidence of dermal sensitization to BALL POWDER<sup>®</sup> was obtained in this study.

Key Words: Dermal Sensitization, Toxicology; ~~BALL POWDER<sup>®</sup>~~, Nitrocellulose; Buehler Test; Guinea Pigs;

*Ball powder propellants; ammunition;*

*Small arms ammunition; 5.56 mm ammunition* ←

Accession For	
NTIS GNA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	



## PREFACE

**TYPE REPORT:** Dermal Sensitization GLP Report

**TESTING FACILITY:** U.S. Army Medical Research and  
Development Command  
Letterman Army Institute of Research  
Presidio of San Francisco, CA 94129-6800

**SPONSOR:** US Army Medical Research and Development Command  
US Army Medical Bioengineering Research and  
Development Laboratory  
Fort Detrick, MD 21701-5010  
Project Officer: Gunda Reddy, PhD

**WORK UNIT:** 3E162720A835, Nitrocellulose-Nitroguanidine  
Projects  
WU 180, TL09

**GLP STUDY NO.:** 84032

**STUDY DIRECTOR:** Don W. Korte Jr, PhD, MAJ, MS

**PRINCIPAL INVESTIGATOR:** Earl W. Morgan, DVM, MAJ, VC  
Diplomate of American College of  
Veterinary Preventive Medicine  
Diplomate, American Board of  
Toxicology

**CO-PRINCIPAL INVESTIGATOR:** John R.G. Ryabik, BS, SP4

**REPORT AND DATA MANAGEMENT:** A copy of the final report,  
study protocols, raw data,  
SOPs, and an aliquot of the  
test compound will be retained  
in the LAIR Archives.

**TEST SUBSTANCE:** BALL POWDER® (Olin WC 844 for cartridge  
5.56 mm, Ball, M193)

**INCLUSIVE STUDY DATES:** 10 Apr - 3 Jun 1985


**OBJECTIVE:** The objective of the study was to evaluate the  
dermal sensitization potential of BALL POWDER®  
in guinea pigs.


#### ACKNOWLEDGMENT


MAJ Larry D. Brown, DVM, SSG James D. Justus, BS, SP4 Steven K. Sano, BS, and Gerald F.S. Hiatt, PhD, provided research assistance; Yvonne C. Johnson, BS, provided statistical and research assistance; SP4 James F. Fisher, Scott L. Schwebe, Richard D. Spieler, and Charlotte L. Speckman provided animal care and facility management; Colleen S. Kamiyama, Brenda Goce and Dianna B. Johnson provided office management during performance of this study and preparation of the report.


SIGNATURES OF PRINCIPAL SCIENTISTS AND MANAGERS INVOLVED IN THE STUDY


We, the undersigned, declare that GLP Study 84032 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

 6 SEP 85  
DON W. KORTE JR., PhD / DATE  
MAJ, MS  
Study Director

  
LANCE O. LOLLINI, DVM / DATE  
LTC, VC  
Pathologist

 30 Aug 85  
EARL W. MORGAN, DVM / DATE  
CPT, VC  
Principal Investigator

 3 Sept 85  
CONRAD R. WHEELER, PhD / DATE  
DAC  
Analytical Chemist

 3 Sept 85  
JOHN R.G. RYABIK, BS / DATE  
SP4, USA  
Co-Principal Investigator



DEPARTMENT OF THE ARMY  
LETTERMAN ARMY INSTITUTE OF RESEARCH  
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-5800

REPLY TO  
ATTENTION OF:

SGRD-ULZ-QA

14 May 1987

MEMORANDUM FOR RECORD

SUBJECT: Report of GLP Compliance


1. I hereby certify that in relation to LAIR GLP Study 84032 the following inspections were made:

23 April 1985 - 1st Induction Dose Applied

10 May 1985 - 72 Hour Score for 3rd Induction Dose

23 May 1985 - 48 Hour Score for Challenge Dose

2. The report and raw data for this study were audited on 15 January 1987.

  
for CAROLYN M. LEWIS  
DAC  
C, Quality Assurance Section



## TABLE OF CONTENTS

	Page
Abstract.....	i
Preface .....	iii
Acknowledgments.....	iv
Signatures of Principal Scientists.....	v
Report of Quality Assurance Unit.....	vi
Table of Contents.....	vii
BODY OF REPORT	
INTRODUCTION	
Objective of Study.....	1
MATERIALS.....	1
Test Substance.....	1
Vehicle for Test Substance.....	3
Positive Control.....	3
Vehicle for Positive Control.....	3
Animal Data.....	3
Husbandry.....	4
METHODS	
Group Assignment/Acclimation.....	4
Dosage Levels.....	4
Compound Preparation.....	4
Test Procedures.....	5
Necropsy.....	6
Duration of Study.....	6
Deviations from Study Protocol.....	6
Raw Data and Final Report.....	7
RESULTS.....	7
DISCUSSION.....	12
Primary Irritation.....	12
Allergic Contact Sensitization.....	13
BALL POWDER®.....	14

Table of Contents (continued)	Page
CONCLUSION.....	14
REFERENCES.....	15
APPENDICES	
Appendix A. Chemical Data.....	19
Appendix B. Animal Data.....	21
Appendix C. Historical Listing of Events.....	23
Appendix D. Individual Dermal Scores.....	27
Appendix E. Pathology Report.....	35
OFFICIAL DISTRIBUTION LIST.....	37

**Dermal Sensitization Potential of BALL POWDER® in Guinea Pigs -- Morgan et al**

Nitroguanidine, a primary component of US Army triple base propellants, is now produced in a Government-owned contractor-operated ammunition plant. The US Army Biomedical Research and Development Laboratory (USABRDL), as part of its mission to evaluate the environmental and health hazards of propellants generated by US Army munitions manufacturing facilities, conducted a review of the nitroguanidine data base and identified significant gaps in the toxicity data (1). The Toxicology Division, LAIR, was tasked by USABRDL to develop a genetic and mammalian toxicity profile for nitroguanidine, related intermediates/by-products of its manufacture, and its environmental degradation. A genetic and acute mammalian toxicity profile of BALL POWDER®, a fielded nitrocellulose-based propellant (cartridge 5.56 mm, Ball, M193) was also requested as a baseline against which future formulations will be compared.

Objective of Study

The objective of this study was to evaluate the dermal sensitization potential of BALL POWDER® in guinea pigs.

**MATERIALS**

Test Substance

Chemical name: BALL POWDER® (Olin WC 844 for cartridge 5.56 mm, Ball, M193). BALL POWDER® is a registered trademark of Olin Winchester Corporation.

Code number: LAIR Code No. TA045

Morgan--2

Chemical Composition:

	Percent
Nitroglycerin	10.235
Dinitrotoluene	0.685
Diphenylamine	1.105
Dibutylphthalate	5.255
Nitrocellulose	83.23
Total Volatiles	1.045
Moisture and Volatiles	0.895
Residual Solvent	0.49
Calcium Carbonate	0.09
Sodium Sulfate	0.12

Source: Badger Army Ammunition Plant  
Baraboo, WI 53913

Other test substance information is presented in Appendix A.

#### Vehicle for Test Substance


Sterile, isotonic saline (Travenol Laboratories, Deerfield, IL) was used as the vehicle for BALL POWDER®. The expiration date for this lot (7C950X0) was October 1985.

#### Positive Control

Chemical name: Dinitrochlorobenzene (DNCB)

Chemical Abstract Service Registry No.: 97-00-7

Structural formula:



Molecular formula:  $C_6H_3N_2O_4Cl$

#### Vehicle for Positive Control

The vehicle for DNCB was a propylene glycol (3%) and isotonic saline (97%) mixture. Propylene glycol (lot number 36485) was obtained from Certified Laboratories, Inc. (Philadelphia, PA). Saline was the same as for the BALL POWDER® vehicle. Other positive control substance information is presented in Appendix A.

#### Animal Data

Forty-six male guinea pigs, Hartley strain, (Charles River, Kingston, NY) were used for this study. They were identified individually with ear tags numbered 85E00134 - 85E00179 inclusive. Two animals were selected randomly for quality control necropsy evaluation on receipt. Two of the animals were used for a pilot study to determine a non-irritating dose level. Animal weights on receipt (11 Apr 85) ranged from 189 to 256 g. Additional animal data are presented in Appendix B.

### Husbandry

Guinea pigs were caged individually in stainless steel wire mesh cages in racks equipped with automatically flushing dump tanks. No bedding was used in any of the cages. The diet, fed ad libitum, consisted of Certified Purina Guinea Pig Chow Diet No. 5026 (Ralston Purina Company, Checkerboard Square, St Louis, MO); water was provided by continuous drip from a central line. The animal room temperature was maintained in a range from 21.7°C to 25.0°C and relative humidity in a range of 32 to 56 percent. The photoperiod was 12 hours of light per day.

### METHODS

This study was conducted in accordance with LAIR SOP-OP-STX-82 "Buehler Dermal Sensitization Test" (2) and EPA guidelines (3).

#### Group Assignment/Acclimation

The guinea pigs were quarantined for 13 days before administration of the first induction dose. During the quarantine period, they were checked daily for signs of illness and weighed once a week. Ten animals were assigned to each of four groups by a stratified randomization technique based on their body weights.

#### Dosage Levels

BALL POWDER® (Olin WC 844) is a smooth, spheroidal pellet 0.5 - 1.5 mm in diameter. Since it is insoluble in water or physiologic solutions, BALL POWDER® was applied neat (without physical or chemical alterations). A pilot study, using BALL POWDER® moistened with isotonic saline, indicated that the neat compound was non-irritating under the conditions of this test.

Two sensitization control groups were included in the study. Dinitrochlorobenzene, a known potent sensitizing agent (4), was applied to one group, at a 0.1% concentration, as a positive control. Isotonic saline was applied to another group as a vehicle control. In addition, a negative control group received BALL POWDER® only on the day of challenge dosing.

#### Compound Preparation

The test compound was prepared<sub>2</sub> by weighing 0.5 g BALL POWDER® and pouring it on a 2.5 cm<sup>2</sup> patch that had been

moistened with 0.5 ml of isotonic saline. The dinitrochlorobenzene dosing solution was prepared by first adding 30 mg DNCB to 1 ml of propylene glycol and heating until it dissolved (approximately 40°C). To this, 29 ml of 0.9% sodium chloride solution were added, to give a final concentration of 0.1% (w/v). This solution was heated to 65°C and vortexed before application to keep the DNCB in solution. DNCB solutions were prepared fresh for each application day.

### Test Procedures

The closed patch dermal sensitization test procedures utilized in this study were developed by Buehler and Griffith (5-7). Test compounds were applied for six hours under a closed patch once a week for three weeks during the induction phase. The same application site was used for each induction dose. To distinguish between reactions from repeated insult and sensitization, duplicate patches of the challenge dose were applied, one on the old site and one on a new site. To distinguish between reactions from primary irritation and sensitization, negative control groups were added which received only the challenge dose.

During the induction phase, the experimental, saline control, and positive control groups were dosed with 0.5 g of the appropriate compound applied topically under a 2.5 cm<sup>2</sup> gauze patch. This procedure was performed for three consecutive weeks (23 Apr, 30 Apr, and 7 May 85). The day before each dosing a 8 cm<sup>2</sup> area on the left side of the animal was clipped with electric clippers (Oster® Model A5, size 40 blade, Sunbeam Corp, Milwaukee, WI) and then shaved with an electric razor (Norelco® Speed Razor Model HP1134® S, North American Phillips Corp, Stamford, CT). The patch was taped with Blenderm® hypo-allergenic surgical tape (3M Corp, St Paul, MN) to the same site each time and the animal was wrapped several times with Vetrap® (3M Corp, St Paul, MN). The patch was left in place for six hours. When the wrap and patch were removed, the area under the patch was marked with surgical felt tip marking pen for ease of scoring.

Animals were challenged two weeks (21 May 85) following the third induction dose. The experimental group and the positive control group received two 0.5 g doses, one applied to the old site on the left side and the other to a new site on the right side. Negative and vehicle control groups only received a single 0.5 g dose which was applied to the left side. The procedures for clipping, shaving, wrapping, and exposure period remained the same.

Since the positive control group exhibited only a weak positive response to the first challenge dose, the animals were re-challenged on 29 May 85. The procedures were the same except the negative control group was not re-challenged.

In Buehler's procedure, skin reactions are scored 24 and 48 hours after the challenge dose only. In the present study, skin reactions were scored 24, 48, and 72 hours after each induction dose as well. Skin reactions were assigned scores according to Buehler's grading system: 0 (no reaction), 1 (slight erythema), 2 (moderate erythema) and 3 (marked erythema). The results are expressed both in terms of incidence (the number of animals showing responses of 1 or greater at either observation time) and severity (the sum of the test scores divided by the number of animals tested). Results from the left side are compared with right side and with the negative control group.

Some modifications of Buehler's procedures were made. Instead of placing animals in restraint during the 6-hour exposure period, the animals were wrapped several times with an elasticized tape to hold the patch in place. Consequently, the animals were able to move about freely in their cage during the exposure period. Buehler and Griffith (7) also recommended depilating the day before the challenge dose. For consistency with induction procedures, this step was replaced by clipping the animals as described previously.

#### Necropsy

All guinea pigs were submitted for a complete gross necropsy at the conclusion of the 14-day observation period.

#### Duration of Study

A historical listing of study events appears in Appendix C.

#### Deviations from Study Protocol

Only two guinea pigs and one "concentration," 100%, were studied in the pilot study. Since the test compound is a hard pellet and insoluble in the preferred vehicle, it was considered unlikely that the compound or one of its constituent chemicals would enter the skin and cause a reaction. Thus the pilot study was reduced to conserve animals.



The DNCB solution was maintained at approximately 65°C prior to dosing. This was necessary to keep the DNCB in solution, but did not result in thermal insult to the animal's skin, as the aliquot for dosing cooled quickly during pipetting and application to the patch. Sufficient sensitization was produced by DNCB with this method.

One guinea pig caught his foot in the caging and broke his leg. He was removed from the study and sacrificed. He was replaced with one of the unused "pilot" guinea pigs.

On 27 Mar 85, the building engineers turned off the exhaust fans and steam system for routine maintenance. During this outage the humidity fluctuated between 44 and 81 percent.

It is believed that these deviations from the protocol did not adversely affect study results.

#### Raw Data and Final Report Storage

A copy of the final report, study protocols, raw data, retired SOPs, and an aliquot of the test compound will be retained in the LAIR Archives.

#### RESULTS

Tables 1, 2, and 3 summarize the incidence of reactions 24, 48, and 72 hours after each dose. There was no reaction observed in response to BALL POWDER®, either at 24, 48, and 72 hours. This lack of response is reflected in Tables 4, 5, and 6 which report the severity of skin reactions at 24, 48, and 72 hours. Response severity for each group is calculated by summing the scores of responding animals and dividing by the total number of animals within that group. This produced a severity index of 0.0 for BALL POWDER®.

In contrast, dinitrochlorobenzene (DNCB) produced a positive response at all time points except the first induction. Between 70% and 100% of the DNCB-treated animals exhibited a response 24 hours following the second and/or third induction and challenge doses. These reactions persisted and yielded scorable effects in 20-100% of the animals at 48 hours after dosing and 10-100% of the animals at 72 hours after dosing.

Severity scores for these responses to DNCB ranged from 0.0 to 1.3 at the 24-hour scoring period (Table 4). The highest score, 1.3, was observed on the left (induction) side in response to the re-challenge dose. By 48 and 72

hours after dosing the reactions had subsided somewhat except for the re-challenge; consequently, the severity range decreased from 0.0 to 0.7 (Tables 5 and 6). However, severity scores for the re-challenge increased slightly from 0.9 to 1.5.

No responses whatsoever were observed in the negative control (challenge dose of BALL POWDER® only) or the vehicle control (normal saline-treated) groups. The individual 24, 48, and 72 hour scores for all animals are provided, by group, in Appendix D.

No lesions were found at necropsy which could be attributed to the test procedure or the test compound. The veterinary pathologist's report appears in Appendix E.

TABLE 1

Incidences of Skin Reactions  
after 24 Hours  
(n=10 in each test group)

Test Group	First	Induction Second	Third	Challenge Left	Right	Re-Challenge Left	Right
BALL POWDER®	0	0	0	0	0	0	0
Negative Control*	---	---	---	0	0	---	---
Saline Vehicle	0	0	0	0	0	0	0
DNCB	0	7	10	8	8	10	10

\*The Negative Control Group received only a challenge dose of the test compound.

TABLE 2

Incidences of Skin Reactions  
after 48 Hours  
(n=10 in each test group)

Test Group	First	Induction Second	Third	Challenge Left	Right	Re-Challenge Left	Right
BALL POWDER®	0	0	0	0	0	0	0
Negative Control*	---	---	---	0	0	---	---
Saline Vehicle	0	0	0	0	0	0	0
DNCB	0	5	7	1	2	10	6

\*The Negative Control Group received only a challenge dose of the test compound.

TABLE 3

Incidences of Skin Reactions  
after 72 Hours  
(n=10 in each test group)

Test Group	First	Induction		Third	Challenge		Re-Challenge	
		Second			Left	Right	Left	Right
BALL POWDER®	0	0		0	0	0	0	0
Negative Control*	---	---		---	0	0	---	---
Saline Vehicle	0	0		0	0	0	0	0
DNCB	0	1		3	1	1	10	6

\*The Negative Control Group received only a challenge dose of the test compound.

TABLE 4

Severity of Skin Reactions  
after 24 Hours

Test Group	First	Induction		Third	Challenge		Re-Challenge	
		Second			Left	Right	Left	Right
BALL POWDER®	0.0	0.0		0.0	0.0	0.0	0.0	0.0
Negative Control*	---	---		---	0.0	0.0	---	---
Saline Vehicle	0.0	0.0		0.0	0.0	0.0	0.0	0.0
DNCB	0.0	0.7		1.2	0.8	0.9	1.3	1.0

\*The Negative Control Group received only a challenge dose of the test compound.

TABLE 5  
Incidences of Skin Reactions  
after 24 Hours

Test Group	First	Induction Second	Third	Challenge Left	Right	Re-Challenge Left	Right
BALL POWDER®	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Negative Control*	---	---	---	0.0	0.0	---	---
Saline Vehicle	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DNCB	0.0	0.5	0.7	0.1	0.2	1.5	0.9

\*The Negative Control Group received only a challenge dose of the test compound.

TABLE 6  
Incidences of Skin Reactions  
after 72 Hours

Test Group	First	Induction Second	Third	Challenge Left	Right	Re-Challenge Left	Right
BALL POWDER®	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Negative Control*	---	---	---	0.0	0.0	---	---
Saline Vehicle	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DNCB	0.0	0.1	0.3	0.1	0.1	1.5	1.0

\*The Negative Control Group received only a challenge dose of the test compound.

## DISCUSSION

Skin reactions arising from direct contact with chemicals are classified as either irritative or sensitizing reactions. Both reactions produce similar inflammatory responses; the primary difference being the basic mechanism responsible for the response.

Primary irritation is direct inflammation in response to injury to the skin produced by the eliciting chemical. Irritation is a locally mediated response ranging from mild, reversible inflammation to severe ulceration progressing to necrosis.

Sensitization is manifested as indirect inflammation mediated by components of the immune system in response to activation by the eliciting chemical (8). Dermal sensitization is usually a delayed hypersensitivity or cellular immunologic reaction. During the induction phase (3 weeks in the present study) there is proliferation of a clone of T lymphocytes specifically sensitized to the eliciting antigen. Upon subsequent exposure to the antigen these T lymphocytes release mediators, lymphokines, which initiate and amplify an inflammatory reaction at the site of contact (9).

Although both irritation and sensitization appear grossly similar in experimental animals, and may even be produced by the same agent, it is possible to distinguish between them. Irritation is an immediate response and can be produced upon first contact with the chemical, whereas sensitization requires at least one innocuous "conditioning" exposure before a reaction can be elicited.

Irritative responses usually require a relatively high concentration or dose of the offending chemical, while sensitization reactions may occur in response to minute quantities. Essentially all individuals in a population will express an irritative response to a reactive chemical, provided the dose is high enough, while only a fraction of the population normally becomes sensitized to the same chemical. A fully developed response can be produced by first contact with an irritant, but initial contact with a sensitizer produces no reaction (a conditioning exposure is necessary). Unless there is accumulation of damage, subsequent exposures to an irritant produce inflammation of essentially similar intensity/severity, while the reaction to a sensitizer increases over 2 to 4 exposures after the initial contact. An irritant produces inflammation of rapid onset with short duration while a sensitization reaction is somewhat delayed and prolonged. The

inflammatory response to an irritant may spread beyond the area of contact while sensitization reactions are usually circumscribed.

The features of irritation and sensitization were applied by Buehler and Griffith (5-7) to establish guidelines for differentiation between the two. In evaluating a dermal sensitization study they recommend comparing the results from a challenge dose in the experimental group with those for the negative control group:

#### Irritative Responses:

- occur in a large proportion of test animals.
- develop in response to the first or second exposure.
- usually fade within 24 to 48 hr, unless damage is severe.
- may be stronger at challenge to a previously unexposed area of skin (contralateral flank).

#### Sensitization Reactions:

- occur in only a few animals, unless the compound is a potent sensitizer.
- are absent after the initial (conditioning) exposure, but appear in response to subsequent exposures.
- develop slowly, the intensity/severity of inflammation being greater at 72 to 96 hr than at 24 to 48 hr.
- increase in intensity/severity from one exposure to the next (at sites previously exposed or unexposed).

Dermal irritancy is evaluated by the method of Draize et al (10) in which the chemical is applied once, at high concentration, and the resulting acute inflammatory response is graded. Evaluation of sensitization potential is accomplished by repeated application at lower non-irritating concentrations, over a few weeks. There is then a latent period, usually two weeks, to allow the immune system to elaborate and increase its specific reactivity to the chemical. A challenge dose is then given and the resulting inflammatory reaction is graded. Analysis of the

incidence, severity and timing of the reaction to the challenge dose gives an estimate of the sensitizing potential of the study compound.

#### BALL POWDER®

In the present study, BALL POWDER® was evaluated for its ability to elicit a delayed-hypersensitivity reaction via dermal contact. As tested by the Buehler and Griffith method (5-7), BALL POWDER® produced no response indicative of dermal sensitization. Therefore in this study BALL POWDER® showed no evidence of potential to elicit an immunologic response.

Because the guinea pig exhibits a somewhat lower sensitizing responsiveness than man, this result does not guarantee that BALL POWDER® will not sensitize humans. It does indicate that BALL POWDER® is unlikely to sensitize humans and its potential is low enough to permit testing in humans.

Any sensitization produced by BALL POWDER® would have been easily detected by this study. A hypersensitivity-type response was reliably elicited by DNCB in the present group of animals. This response to DNCB was characteristic of that observed previously within the Institute (11). Although DNCB is capable of producing primary irritation, the characteristics of responses observed in this study are indicative of a reaction due to sensitization. The concentration of DNCB used for induction and challenge is too low to produce primary irritation. Also, the response to DNCB was observed only after two or more exposures and the severity and persistency generally increased with the number of previous exposures.

#### CONCLUSION

BALL POWDER®, based on a zero percent sensitization rate in this study, exhibited no potential for inducing dermal sensitization.



# REFERENCES

1. Kenyon KF. A data base assessment of environmental fate aspects of nitroguanidine. Frederick, Maryland: US Army Medical Bioengineering Research and Development Laboratory, 1982; DTIC No. ADA 125591.
2. Buehler dermal sensitization test. LAIR Standard Operating Procedure OP-STX-82, Presidio of San Francisco, California: Letterman Army Institute of Research, 18 May 1984.
3. Environmental Protection Agency. Office of Pesticides and Toxic Substances, Office of Toxic Substances (TS-792). Dermal sensitization. In: Health effects test guidelines. Washington, DC: Environmental Protection Agency, August 1982; EPA 560/6-82-001.
4. Landsteiner K, Jacobs J. Studies on sensitization of animals with simple chemical compounds. J Exp Med 1935; 61:643-656.
5. Buehler EV. Delayed contact hypersensitivity in the guinea pig. Arch Dermatol 1965; 91:171-175.
6. Griffith JF. Predictive and diagnostic testing for contact sensitization. Toxicol Appl Pharmacol 1969; Suppl 3:90-102.
7. Buehler EV, Griffith JF. Experimental skin sensitization in the guinea pig and man. In: Maibach HI, ed. Animal models in dermatology. Edinburgh: Churchill Livingstone, 1975:56-65.
8. Mathias CGT. Clinical and experimental aspects of cutaneous irritation. In: Marzulli FN, Maibach HI, eds. Dermatotoxicology. Washington: Hemisphere Publishing Corporation, 1983:167-168.
9. Paul WE. Fundamental immunology. New York: Raven Press, 1984:685-694.
10. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944; 82:377-390.

11. Lewis CM, Johnson YC, Korte DW. Dermal sensitization potential of the Holston compounds: virgin DMSO, DMSO recycle solvent, and DMSO evaporator sludge. Toxicology Series 70. Presidio of San Francisco, CA: Letterman Army Institute of Research, 1984. Institute Report No. 172.

	Page
Appendix A. Chemical Data.....	19
Appendix B. Animal Data.....	21
Appendix C. Historical Listing of Events.....	23
Appendix D. Individual Dermal Scores.....	27
Appendix E. Pathology Report.....	35

APPENDICES

## APPENDIX A

ANIMAL DATA

Species: *Cavia porcellus*

Strain: Hartley

Source: Charles River Kingston, NY

Sex: Male

Date of birth: 23 March 1985

Method of randomization: Weight bias, stratified animal allocation

Animals in each group: 10 male animals

Condition of animals at start of study: Normal

Identification procedures: Ear tagging procedure, tag numbers 85E00134 to 85E00179 inclusive.

Pretest conditioning: Quarantine/acclimation 10 Apr - 22 Apr 1985

Justification: The laboratory guinea pig has proven to be a sensitive and reliable model for detection of delayed hypersensitivity from dermal contact.

## HISTORICAL LISTING OF EVENTS

Date	Event
10 Apr 85	Forty-six animals arrived, were examined, placed in cages, and fed.
11 Apr 85	Animals were ear-tagged and weighed. Two animals were submitted for necropsy as quality controls.
10 Apr-3 Jun 85	Animals were checked daily.
1,16,22,29 Apr, 6,13,20,28	Animals were weighed.
May 85 15 Apr 85	Four pilot animals were randomly selected and two were shaved. Pilot doses were prepared.
16 Apr 85	Pilot animals were patch tested. One animal was sacrificed due to a broken leg.
17 Apr 85	Pilot animals were scored for 24-hour skin reaction.
18 Apr 85	Pilot animals were scored for 48-hour skin reaction. Pilot results evaluated, test concentration determined.
22 Apr 85	Animals were randomized into groups.

Date	Event
22,29 Apr, 6 May 85	Test animals, except negative control group, were clipped and shaved. Doses were prepared.
23,30 Apr, 7 May 87	Test animals, except negative control group, were given induction dose.
24 Apr, 1,8 May 86	Test animals, except negative control group, were scored for 24-hour skin reaction.
25 Apr, 2,9 May 86	Test animals, except negative control group, were scored for 48-hour skin reaction.
26 Apr, 3,10 May 86	Test animals, except negative control group, were scored for 72-hour skin reaction.
20 May 85	Test animals were clipped and shaved. Doses were prepared.
21 May 85	Test animals were given challenge dose.
22 May 85	Test animals were scored for 24-hour skin reaction.
23 May 85	Test animals were scored for 48-hour skin reaction.

Date	Event
28 May 85	Test animals, except negative control group, were clipped and shaved. Doses were prepared.
29 May 85	Test animals, except negative control group, were given induction dose.
30 May 85	Test animals, except negative control group, were scored for 24-hour skin reaction.
1 May 85	Test animals, except negative control group, were scored for 48-hour skin reaction.
2 May 85	Test animals, except negative control group, were scored for 72-hour skin reaction.
3 May 85	Animals were observed and delivered to Necropsy Suite for sacrifice and gross necropsy.



Individual Dermal Scores

	Page
Table 1. BALL POWDER®.....	24
Table 2. Dinitrochlorobenzene.....	26
Table 3. Saline.....	28
Table 4. Negative.....	30

INDIVIDUAL DERMAL SCORES  
BALL POWDER® STUDY GROUP

ANIMAL NUMBER	INDUCTION 1			INDUCTION 2			INDUCTION 3			CHALLENGE (LEFT/RIGHT)				
	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	72H
85E0135	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0140	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0144	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0156	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0167	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0169	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0170	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0171	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0176	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0178	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AVERAGE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

## INDIVIDUAL DERMAL SCORES

## BALL POWDER® STUDY GROUP

RE-CHALLENGE DOSING						
ANIMAL NUMBER	LEFT FLANK			RIGHT FLANK		
	24H	48H	72H	24H	48H	72H
85E0135	0.0	0.0	0.0	0.0	0.0	0.0
85E0140	0.0	0.0	0.0	0.0	0.0	0.0
85E0144	0.0	0.0	0.0	0.0	0.0	0.0
85E0156	0.0	0.0	0.0	0.0	0.0	0.0
85E0167	0.0	0.0	0.0	0.0	0.0	0.0
85E0169	0.0	0.0	0.0	0.0	0.0	0.0
85E0170	0.0	0.0	0.0	0.0	0.0	0.0
85E0171	0.0	0.0	0.0	0.0	0.0	0.0
85E0176	0.0	0.0	0.0	0.0	0.0	0.0
85E0178	0.0	0.0	0.0	0.0	0.0	0.0
AVERAGE	0.0	0.0	0.0	0.0	0.0	0.0

## INDIVIDUAL DERMAL SCORES

## DNCB POSITIVE CONTROL GROUP

ANIMAL NUMBER	INDUCTION 1			INDUCTION 2			INDUCTION 3			CHALLENGE (LEFT/RIGHT)					
	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	48H	72H
85E0134	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0137	0.0	0.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0138	0.0	0.0	0.0	1.0	1.0	1.0	2.0	1.0	1.0	1.0	0.0	0.0	1.0	0.0	0.0
85E0139	0.0	0.0	0.0	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0
85E0157	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
85E0160	0.0	0.0	0.0	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	2.0	0.0	0.0
85E0162	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0
85E0166	0.0	0.0	0.0	1.0	0.0	0.0	2.0	1.0	1.0	2.0	1.0	1.0	1.0	0.0	0.0
85E0175	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	0.0	0.0
85E0179	0.0	0.0	0.0	1.0	1.0	0.0	1.0	1.0	0.0	1.0	0.0	0.0	1.0	1.0	1.0
AVERAGE	0.0	0.0	0.0	0.7	0.5	0.1	1.2	0.7	0.3	0.8	0.1	0.1	0.9	0.2	0.1

## INDIVIDUAL DERMAL SCORES

## DNCB POSITIVE CONTROL GROUP

RE-CHALLENGE DOSING						
ANIMAL NUMBER	LEFT FLANK			RIGHT FLANK		
	24H	48H	72H	24H	48H	72H
85E0134	1.0	1.0	1.0	1.0	0.0	0.0
85E0137	2.0	2.0	1.0	1.0	1.0	1.0
85E0138	2.0	2.0	2.0	1.0	2.0	2.0
85E0139	1.0	1.0	2.0	1.0	1.0	1.0
85E0157	1.0	2.0	2.0	1.0	2.0	1.0
85E0160	1.0	2.0	2.0	1.0	2.0	2.0
85E0162	1.0	1.0	1.0	1.0	0.0	0.0
85E0166	2.0	1.0	2.0	1.0	1.0	2.0
85E0175	1.0	1.0	1.0	1.0	0.0	0.0
85E0179	1.0	2.0	1.0	1.0	0.0	0.0
AVERAGE	1.3	1.5	1.5	1.0	0.9	1.0

INDIVIDUAL DERMAL SCORES  
NORMAL SALINE VEHICLE CONTROL GROUP

ANIMAL NUMBER	INDUCTION 1			INDUCTION 2			INDUCTION 3			CHALLENGE (LEFT/RIGHT)					
	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	48H	72H	24H	48H	72H
85E0136	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0143	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0145	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0147	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0151	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0158	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0159	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0161	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0164	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
85E0168	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AVERAGE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

NORMAL SALINE VEHICLE CONTROL GROUP  
INDIVIDUAL DERMAL SCORES

RE-CHALLENGE DOSING						
ANIMAL NUMBER	LEFT FLANK			RIGHT FLANK		
	24H	48H	72H	24H	48H	72H
85E0136	0.0	0.0	0.0	0.0	0.0	0.0
85E0143	0.0	0.0	0.0	0.0	0.0	0.0
85E0145	0.0	0.0	0.0	0.0	0.0	0.0
85E0147	0.0	0.0	0.0	0.0	0.0	0.0
85E0151	0.0	0.0	0.0	0.0	0.0	0.0
85E0158	0.0	0.0	0.0	0.0	0.0	0.0
85E0159	0.0	0.0	0.0	0.0	0.0	0.0
85E0161	0.0	0.0	0.0	0.0	0.0	0.0
85E0164	0.0	0.0	0.0	0.0	0.0	0.0
85E0168	0.0	0.0	0.0	0.0	0.0	0.0
AVERAGE	0.0	0.0	0.0	0.0	0.0	0.0

## INDIVIDUAL DERMAL SCORES

## BALL POWDER® NEGATIVE CONTROL GROUP

ANIMAL NUMBER	CHALLENGE DOSING					
	LEFT FLANK			RIGHT FLANK		
	24H	48H	72H	24H	48H	72H
85E0141	0.0	0.0	0.0	0.0	0.0	0.0
85E0148	0.0	0.0	0.0	0.0	0.0	0.0
85E0149	0.0	0.0	0.0	0.0	0.0	0.0
85E0150	0.0	0.0	0.0	0.0	0.0	0.0
85E0153	0.0	0.0	0.0	0.0	0.0	0.0
85E0154	0.0	0.0	0.0	0.0	0.0	0.0
85E0155	0.0	0.0	0.0	0.0	0.0	0.0
85E0163	0.0	0.0	0.0	0.0	0.0	0.0
85E0172	0.0	0.0	0.0	0.0	0.0	0.0
85E0173	0.0	0.0	0.0	0.0	0.0	0.0
AVERAGE	0.0	0.0	0.0	0.0	0.0	0.0



LAIR Gross Pathology Report  
GLP Study 84032

Study: GLP #84032, Toxicology Services Group

Test: Buehler Dermal Sensitization

Investigator: CPT Morgan

Test Substance: BALL POWDER®


History: Study conducted in accordance with SOP-OP-STX-82. Number of animals: 40. Sex: male Species: Guinea pig, Hartley Albino.

Findings:

<u>Group</u>	<u>Animals/Group</u>	<u>Lesions</u>
Test compound	10	0
Positive control (DNCEB)	10	0
Saline	10	0
Negative control	10	1*

\*Animal number 85E00149 had a discrete focal yellow (2 x 12 mm) area on the liver. Microscopically there were a few discrete (5 mm or less in diameter) subcapsular foci of coagulative necrosis bordered by a prominent layer of collapsed stroma/fibrosis and a marked infiltrate of macrophages.

Comments: The liver lesion was considered incidental and in no way related to the procedure or test compound. This type of lesion is frequently seen in guinea pigs.

  
G. TRACY MAKOVEC, DVM

CPT, VC

Pathology Services Group

  
LANCE O. TOLLINI, DVM

LTC, VC

Chief, Pathology Services Group

10 June 1985

OFFICIAL DISTRIBUTION LIST

Commander  
US Army Medical Research  
and Development Command  
ATTN: SGRD-RMS/Mrs. Madigan  
Fort Detrick, MD 21701-5012

Defense Technical Information Center  
ATTN: DTIC/DDAB (2 copies)  
Cameron Station  
Alexandria, VA 22304-6145

Office of Under Secretary of Defense  
Research and Engineering  
ATTN: R&AT (E&LS), Room 3D129  
The Pentagon  
Washington, DC 20301-3080

The Surgeon General  
ATTN: DASG-TLO  
Washington, DC 20310

HQ DA (DASG-ZXA)  
WASH DC 20310-2300

Commandant  
Academy of Health Sciences  
US Army  
ATTN: HSHA-CDM  
Fort Sam Houston, TX 78234-6100

Uniformed Services University  
of Health Sciences  
Office of Grants Management  
4301 Jones Bridge Road  
Bethesda, MD 20814-4799

US Army Research Office  
ATTN: Chemical and Biological  
Sciences Division  
PO Box 12211  
Research Triangle Park, NC 27709-2211

Director  
ATTN: SGRD-UWZ-L  
Walter Reed Army Institute  
of Research  
Washington, DC 20307-5100

Commander  
US Army Medical Research Institute  
of Infectious Diseases  
ATTN: SGRD-ULZ-A  
Fort Detrick, MD 21701-5011

Commander  
US Army Medical Bioengineering  
Research & Development Laboratory  
ATTN: SGRD-UBG-M  
Fort Detrick, Bldg 568  
Frederick, MD 21701-5010

Commander  
US Army Medical Bioengineering  
Research & Development Laboratory  
ATTN: Library  
Fort Detrick, Bldg 568  
Frederick, MD 21701-5010

Commander  
US Army Research Institute  
of Environmental Medicine  
ATTN: SGRD-UE-RSA  
Kansas Street  
Natick, MA 01760-5007

Commander  
US Army Institute of Surgical Research  
Fort Sam Houston, TX 78234-6200

Commander  
US Army Research Institute  
of Chemical Defense  
ATTN: SGRD-UV-AJ  
Aberdeen Proving Ground, MD 21010-5425

Commander  
US Army Aeromedical Research Laboratory  
Fort Rucker, AL 36362-5000

AIR FORCE Office of Scientific  
Research (NL)  
Building 410, Room A217  
Bolling Air Force Base, DC 20332-6448

Commander  
USAFSAM/TSZ  
Brooks Air Force Base, TX 78235-5000

Head, Biological Sciences Division  
OFFICE OF NAVAL RESEARCH  
800 North Quincy Street  
Arlington, VA 22217-5000